Asia Pacific Cancer Immunotherapy Market Research Report, Type of Therapy (Monoclonal Antibodies, Cancer Vaccines, Immunomodulators), Application (Lung Cancer, Blood Cancer, Melanoma, Breast Cancer), End User (Hospitals and Clinics, Research Laboratories, Cancer Institute) - Forecasted till 2027

Asia Pacific Cancer Immunotherapy Market Scenario:

Cancer is condition of uncontrolled cell growth. It is one of the deadliest disease in the world and the second major cause for death.  Cancer can be defined as an abnormal cell growth with the potential to spread to other part of the body. There are over 100 types of cancer which has affected human. According to survey carried out by Pfizer, in 2012, 6.7 million of cancer cases was registered in Asia Pacific region which will increasing continuously. Additionally, according to the American Cancer Society, in 2015, 4.2 newly diagnosed invasive cancer cases were registered in China. During last decade, there is a significant increase in the number of patients suffering from different types of cancer. Smoking is one of the most risk factor for the cause of the cancer. Due to deteriorating lifestyle, smoking, and alcoholism there is a rise in the incident of cancer. Increasing cancer population is the major reason for increasing the asia pacific cancer immunotherapy market. Different treatment are available in the market but the advantage of immunotherapy is its high effectiveness compare with other therapy. This therapy is effective for patient suffering from melanoma cancer where chemotherapy and other radiation therapy did not work. Increasing government support for research & development and increasing healthcare expenditure have fuelled the market growth. However, side effect of the treatments and high cost of the therapy may slow the cancer immunotherapy market growth during the forecasted period.

Asia Pacific immunotherapy market is expecting a sound growth of CAGR of 15.5% during the forecasted period 2017-2023.

 Figure 1- Asia Pacific cancer immunotherapy market, by type of therapy

 Sources: Annual reports, Press release, White paper, Company Presentation

Segmentation 

Asia Pacific cancer immunotherapy market is segmented on the basis of type of therapy, application and end users.

On the basis of type of therapy, the market is segmented into monoclonal antibodies, cancer vaccines, immunomodulators and other.

On the basis of application the market is segmented as lung cancer, blood cancer, melanoma, breast cancer and other.

On the basis of end user, the market is segmented into hospitals & clinics, research laboratories, cancer institute and others.

Regional Analysis 

Asia Pacific cancer immunotherapy market is segmented into Japan, China, India, Australia, Republic of Korea and Rest of Asia Pacific. The major driving factor for the market is increasing number of patient population in India and China. China and India are the major contributor in the Asia Pacific cancer immunotherapy market. According to the NCIP, 0.33 million of the people in India are suffering from cancer and the number is continuously increasing owing to the changing lifestyle. Moreover, presence of huge patient population and increasing government support for research & development will fuel the growth of the market in India. China holds the second largest market for cancer immunotherapy market which is followed by Japan. Increasing government support, rapidly developing economy and increasing healthcare expenditure will boost the growth of China and Japan market. Moreover, availability of highly skilled healthcare professionals and rising acceptance of these therapies and increasing demand for the treatment have provided push for the growth of the market in these countries. Australia and Rest of Asia Pacific contribute the least share in the market.

Market Assessment

Sources: Annual reports, Press release, White paper, Company Presentation

Key Players in the cancer immunotherapy market

The key players for the cancer immunotherapy market are Amgen, Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), AstraZeneca Plc. (UK), GlaxoSmithKline Plc. (UK), Bayer AG (Germany),  F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (US), Janssen Biotech, Inc. (US),  Sanofi (France), AbbVie Inc. (US), Takeda Pharmaceuticals (Japan), Oncomed Pharmaceuticals (US) and Immunomedics (US)

Intended Audience

• Government and private research companies


• Research and Development (R&D) Companies


• Drug Manufacturers and Suppliers


• Pharmaceutical Companies


• Medical Research Laboratories

 

Report Scope:

Report Attribute/Metric	Details
Market Size	2027: Significant Value
CAGR	2023: 15.5%
Base Year	2019
Forecast Period	2027
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Type Of Therapy, Application And End Users
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Amgen, Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), AstraZeneca Plc. (UK), GlaxoSmithKline Plc. (UK), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (US), Janssen Biotech, Inc. (US), Sanofi (France), AbbVie Inc. (US), Takeda Pharmaceuticals (Japan), Oncomed Pharmaceuticals (US) and Immunomedics (US)
Key Market Opportunities	Increasing government support for research & development Increasing healthcare expenditure
Key Market Drivers	Increasing cancer population Increasing owing to the changing lifestyle

Speak to Analyst Ask for Customization